Clinical trial
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine…
NCT00002418 · Bristol-Myers Squibb, Industry · Terminated
Key facts
| NCT number | NCT00002418 |
|---|---|
| Title | The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors |
| Official title | A Phase II, 24-Week, Open-Label Study Designed to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Novel Combination Therapy With Videx (Didanosine), Zerit (Stavudine), Viramune (Nevirapine), and MKC-442 (With or Without Hydroxyurea) for the Treatment of HIV-1 Infection in… |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Collaborators | Boehringer Ingelheim Industry Triangle Pharmaceuticals |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Emivirine, Hydroxyurea, Nevirapine, Stavudine, Didanosine |
| Enrollment | 25 |
| First posted | Aug 31, 2001 |
| Last update posted | Aug 14, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: